Advertisement Accuray, University of Heidelberg collaborate for radiation oncology research - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Accuray, University of Heidelberg collaborate for radiation oncology research

Accuray has signed a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution.

Accuray and the University of Heidelberg will join forces on radiation oncology research to progress treatment technology.

Accuray president and chief executive officer Euan Thomson said: "As the premier radiation oncology company with market-leading technologies for image-guided IMRT and radiosurgery, we believe partnerships such as this can make huge inroads in advancing treatment technologies and improving patient care."

University of Heidelberg Oncology Department of Radiation director Jurgen Debus said: "We have a long history using TomoTherapy technologies and have seen the benefits they offer cancer patients, so we are eager to explore further scientific advancements together."